MEF2C-AS2

Across TCGA pan-cancer cohorts, MEF2C-AS2 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated MEF2C-AS2 data layer.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MEF2C-AS2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MEF2C-AS2 expression acts as an unfavorable survival marker, although some lineages such as PRAD and ESCA show a favorable association.

UCEC, READ, and CHOL are the cancer types where MEF2C-AS2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Tertile	III,IV	0.104	0.624	<.001	96	view →
READ	OS	Tertile	IV	0.111	0.893	<.001	63	view →
CHOL	OS	Tertile	II,III,IV	0.019	0.765	.001	45	view →
CESC	OS	Tertile	IV	0.167	0.612	.008	36	view →
TGCT	OS	Tertile	III,IV	0.501	1.000	.014	36	view →
OV	DFS	Tertile	IV	0.163	0.474	.003	24	view →
PAAD	DFS	Tertile	III,IV	0.118	0.734	.014	18	view →
KIRP	DFS	Tertile	III,IV	0.177	0.625	.031	18	view →
KIRC	DFS	Median	IV	0.304	0.545	.018	14	view →
PRAD	DFS	Tertile	All	0.931	0.752	.041	12	view →
LAML	DFS	Quartile	All	0.316	0.582	.022	12	view →
THYM	DFS	Tertile	III,IV	0.205	0.774	.007	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

MEF2C-AS2–UCEC (OS)

Open the UCEC breakdown →